CN104095832A - Liver fibrosis prevention medicine and preparation method thereof - Google Patents
Liver fibrosis prevention medicine and preparation method thereof Download PDFInfo
- Publication number
- CN104095832A CN104095832A CN201410322989.8A CN201410322989A CN104095832A CN 104095832 A CN104095832 A CN 104095832A CN 201410322989 A CN201410322989 A CN 201410322989A CN 104095832 A CN104095832 A CN 104095832A
- Authority
- CN
- China
- Prior art keywords
- anistree
- alcohol
- hepatic fibrosis
- flos caryophylli
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract description 10
- 230000002265 prevention Effects 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 241000628997 Flos Species 0.000 claims description 39
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 33
- 230000003203 everyday effect Effects 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- -1 antiseptic Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- CFWKXAWFAQXEAK-UHFFFAOYSA-N 2,4-bis(2-hydroxy-5-prop-2-enylphenyl)-6-prop-2-enylphenol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=C(O)C(C=2C(=CC=C(CC=C)C=2)O)=C1 CFWKXAWFAQXEAK-UHFFFAOYSA-N 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 2
- 150000002611 lead compounds Chemical class 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 239000005445 natural material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 13
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 229950005499 carbon tetrachloride Drugs 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000561683 Illicium dunnianum Species 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000720991 Illicium Species 0.000 description 1
- 241000561681 Illicium fargesii Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses liver fibrosis prevention medicine and a preparation method thereof. The medicine comprises a main effective constituent, namely macranthol; the using dosage of the medicine is 5-50 mg/70 kg weight per day according to the macranthol; the macranthol is wide in source and can be directly extracted and separated from natural substances, and the extraction and the separation are simple and convenient to operate, so that the liver fibrosis prevention medicine produced from the macranthol has the characteristic of low cost; the macranthol, as a natural medicine, has been used for a long time as a traditional medicine, so that the macranthol is high in using safety as a medicine; in addition, the liver fibrosis prevention medicine has a better liver fibrosis prevention effect, so that the macranthol, as a substance for preventing liver fibrosis or related lead compounds, is used for pharmaceutical production, and the source of natural medicine for liver fibrosis prevention is further broadened.
Description
Technical field
The invention belongs to liver disease drug technical field, be specifically related to a kind of control hepatic fibrosis medicines and preparation method thereof.
Background technology
The anistree alcohol (Macranthol, its chemical structural formula is as follows) of Flos Caryophylli, molecular formula C
27h
26o
3, molecular weight is 398, CAS:123941-73-1.
The anistree alcohol of Flos Caryophylli is the separated a kind of lignin compound obtaining in Illicium plant bark.At present less to the report of its pharmacological action, only find that it has the effect of neuroprotective unit (Moriyama M, Huang JM, Yang CS, et al.Two new sesquiterpenoids and two new prenylated phenylpropanoids from Illicium fargesii, and neuroprotective activity of macranthol.Chem Pharm Bull.2008; 56:1201-4.) and the effect of Cure of depression (Li J, Geng D, Xu J, et al.Antidepressant-like effect of macranthol isolated from Illicium dunnianum tutch in mice.Eur J Pharmacol.2013; 707:112-9.).
Hepatic fibrosis refers to by connective tissue paraplasm in liver due to various virulence factors, cause diffusivity extracellular matrix in liver excessively precipitation pathological process it be not an independently disease, but many chronic hepatic diseases all can cause hepatic fibrosis.It is the only stage which must be passed by that multiple chronic hepatopathy develops into liver cirrhosis, how hepatic fibrosis is reversed in early days, thereby the formation of blocking-up liver cirrhosis is an important ring of liver function protecting.The traditional Chinese medical science thinks, hepatic fibrosis basic pathogenesis is evil Sheng of just declining, the damp and hot blood stasis of not holding concurrently to the greatest extent, stagnation of liver-QI spleen kidney qi blood deficiency.Stagnation of QI due to depression of the liver, causes blood stasis, and channel tunnel blocks, not nourishing the liver of blood, and key is blood stasis.Blood stasis shows that on the pathology of chronic hepatitis, liver cirrhosis be exactly the formation of hepatic fibrosis.For the treatment of hepatic fibrosis, there is no at present desirable medicine.
Summary of the invention
The object of the invention is to overcome prior art defect, a kind of control hepatic fibrosis medicines is provided.
Another object of the present invention is to provide above-mentioned control hepatic fibrosis medicament preparation.
A further object of the present invention is to provide the application of the anistree alcohol of a kind of Flos Caryophylli in preparation control hepatic fibrosis medicines.
Concrete technical scheme of the present invention is as follows:
A control hepatic fibrosis medicines, comprises the anistree alcohol of main effective ingredient Flos Caryophylli, and its application dose is calculated as 5～50mg/70kg body weight every day with the anistree alcohol of Flos Caryophylli.
In a preferred embodiment of the invention, its application dose is calculated as 5～40mg/70kg body weight every day with the anistree alcohol of Flos Caryophylli.
In a preferred embodiment of the invention, also comprise one or more in filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, solvent, surfactant, flavouring agent, antiseptic, lubricant, sweeting agent and pigment.
In a preferred embodiment of the invention, this control hepatic fibrosis medicines is tablet, capsule, granule or syrup.
Prevent and treat a preparation method for hepatic fibrosis medicines, this medicine is tablet, comprises the steps:
(1) accurately take the component of following weight portion:
(2) by the anistree alcohol of above-mentioned Flos Caryophylli, microcrystalline Cellulose, stearic acid, lactose and micropowder silica gel mix homogeneously, granulation;
(3) in above-mentioned granule, add above-mentioned magnesium stearate, mix rear tabletting, obtain described control hepatic fibrosis medicines.
In a preferred embodiment of the invention, described step (1) is: the component that accurately takes following weight portion:
The application of the anistree alcohol of a kind of Flos Caryophylli in preparation control hepatic fibrosis medicines.
In a preferred embodiment of the invention, the application dose of the anistree alcohol of Flos Caryophylli is 5～50mg/70kg body weight every day.
Further preferred, the application dose of the anistree alcohol of Flos Caryophylli is 5～40mg/70kg body weight every day.
The invention has the beneficial effects as follows:
1, the anistree alcohol wide material sources of the main effective ingredient Flos Caryophylli of control hepatic fibrosis medicines of the present invention, can from natural materials, directly extract and be isolated, and extract the easy and simple to handle of separation, therefore have the control hepatic fibrosis medicines of its production to have the advantages that cost is low;
2, the anistree alcohol of the main effective ingredient Flos Caryophylli of control hepatic fibrosis medicines of the present invention is as a kind of natural drug, and its time of using as conventional medicament is remote, and the anistree alcohol of Flos Caryophylli is safe as drug use;
3, control hepatic fibrosis medicines of the present invention has good control hepatic fibrosis effect, thereby can be using the anistree alcohol of Flos Caryophylli as control hepatic fibrosis material or relevant lead compound and for pharmaceutical manufacturing, and then the source of having widened control hepatic fibrosis natural drug.
Accompanying drawing explanation
Fig. 1 is the result statistics block diagram of the anistree alcohol of Flos Caryophylli to tetrachloro-methane induction acute hepatic injury mice serum glutamic pyruvic transminase (ALT) in the embodiment of the present invention 3, " ## " represents P<0.01, compared significant difference with blank group (Control); " * " represents P<0.05; " * * " represents P<0.01, compared significant difference with model control group (Model);
Fig. 2 is the result statistics block diagram of the anistree alcohol of Flos Caryophylli to tetrachloro-methane induction acute hepatic injury mice serum glutamic oxalacetic transaminase (AST) in the embodiment of the present invention 3, " ## " represents P<0.01, compared significant difference with blank group (Control); " * " represents P<0.05; " * * " represents P<0.01, compared significant difference with model control group (Model);
Fig. 3 is the result statistics block diagram of the anistree alcohol of Flos Caryophylli to tetrachloro-methane induction acute hepatic injury mice serum alkaline phosphatase (ALP) in the embodiment of the present invention 3, " ## " represents P<0.01, compared significant difference with blank group (Control); " * " represents P<0.05; " * * " represents P<0.01, compared significant difference with model control group (Model);
Fig. 4 is the result statistics block diagram of the anistree alcohol of Flos Caryophylli to tetrachloro-methane induction acute hepatic injury mice Liver Superoxide Dismutase Activity (SOD) in the embodiment of the present invention 3, " ## " represents P<0.01, compared significant difference with blank group (Control); " * " represents P<0.05; " * * " represents P<0.01, compared significant difference with model control group (Model);
Fig. 5 is the result statistics block diagram of the anistree alcohol of Flos Caryophylli to tetrachloro-methane induction acute hepatic injury mice liver malonaldehyde (MDA) in the embodiment of the present invention 3, " ## " represents P<0.01, compared significant difference with blank group (Control); " * " represents P<0.05; " * * " represents P<0.01, compared significant difference with model control group (Model).
The specific embodiment
By the specific embodiment, by reference to the accompanying drawings technical scheme of the present invention is further detailed and is described below.
Embodiment 1
A control hepatic fibrosis medicines, comprises the anistree alcohol of main effective ingredient Flos Caryophylli, and its application dose is calculated as 5～50mg/70kg body weight every day with the anistree alcohol of Flos Caryophylli, preferred, with the anistree alcohol of Flos Caryophylli, is calculated as 5～40mg/70kg body weight every day.This medicine also can comprise one or more in filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, solvent, surfactant, flavouring agent, antiseptic, lubricant, sweeting agent and pigment.This control hepatic fibrosis medicines is tablet, capsule, granule or syrup.
A preparation method for above-mentioned control hepatic fibrosis medicines, this medicine is tablet, comprises the steps:
(1) accurately take the component of following weight portion:
Preferred:
(2) by the anistree alcohol of above-mentioned Flos Caryophylli, microcrystalline Cellulose, stearic acid, lactose and micropowder silica gel mix homogeneously, granulation;
(3) in above-mentioned granule, add above-mentioned magnesium stearate, mix rear tabletting, obtain described control hepatic fibrosis medicines.
In the test of the following example 2 to 5, in the result statistics block diagram that each model control group is drawn in corresponding experimental result, abscissa all adopts Model mark, and each blank group abscissa in the result statistics block diagram that experimental result is drawn accordingly all adopts Control mark.
Embodiment 2 alcohol extraction chromatographys extract the anistree alcohol of separated Flos Caryophylli
The Flos Carthami of 3.5kg anistree (Illicium dunnianum Tutch) is ground into powder; Take 95% ethanol as extracting solvent, and 60 ℃ of reflux, extract, 2 hours, reclaim solvent and obtain its ethanol extraction; Use afterwards petroleum ether dissolution gained ethanol extraction, and adopt silica gel column chromatography separated, and with petroleum ether-ethyl acetate system gradient elution, co-elute goes out 16 components; (the chloroform: methanol=7:3) (methanol: water=3:7) column chromatography is purified can obtain the anistree alcohol (374mg) of Flos Caryophylli for column chromatography and ODS of the 16th Sephadex LH-20 for component after eluting.
The anistree alcohol of embodiment 3 Flos Caryophylli causes the protective effect of chmice acute chemical liver injury to carbon tetrachloride
(1) laboratory animal: male ICR mouse is bought from Fujian university of TCM Experimental Animal Center, body weight 22-26g, credit number is SCXK (Fujian) 2010-0001; Animal is placed in the cage of 320 * 180 * 160cm, 8, every cage, and mice conforms one week; In whole experimentation, give the mice feed of freely intaking, ambient temperature is 22 ± 2 ℃, and relative humidity is 55 ± 5%, illumination every day 12 hours (morning 7 to point in evenings 7).
(2) medicine configuration: positive drug bifendate (BIF) is configured to the medicinal liquid of 100mg/10ml; The anistree alcohol of Flos Caryophylli is configured to three dosage medicinal liquids of 10mg/ml, 20mg/ml, 40mg/ml.
(3) animal grouping and administering mode: 60 of mices, be divided into 6 groups, every group 10, be respectively Normal group (normal saline), dosage group (40mg/kg), the anistree alcohol high dose group (80mg/kg) of Flos Caryophylli in model control group (normal saline), positive drug bifendate group (100mg/kg), the anistree alcohol low dose group (20mg/kg) of Flos Caryophylli, the anistree alcohol of Flos Caryophylli; Press Mouse Weight 10ml/kg gastric infusion, be administered once, tail test is hanged in administration after 1 hour.
(4) experimental technique: the corresponding medicine of gavage every day 1 time, continuous 7 days, with 2h after last administration, Normal group lumbar injection 10mg/kg olive oil, all the other 5 groups equal lumbar injection 0.1% carbon tetrachloride 10mg/kg, after fasting 16h, from mice clump posterior orbit venous blood sampling, adopt conventional kit method to measure glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), alkali phosphatase (ALP) activity in mice serum; And the level of liver superoxide dismutase (SOD) and hepatic tissue malonaldehyde (MDA).
(5) statistical method: experimental result adopts one factor analysis of variance in conjunction with Dunnett ' s postmortem analysis; With P value, be less than 0.05 expression significant difference significance.
(6) experimental result refers to Fig. 1 to Fig. 5, one factor analysis of variance, and significantly raise in mice serum ALT, AST and ALP of carbon tetrachloride is active, reduces the content of liver SOD activity and rising liver MDA.Dunnett ' s postmortem analysis shows, the anistree basic, normal, high dosage group of alcohol of Flos Caryophylli and positive drug bifendate group all can significantly reduce carbon tetrachloride and cause the too high ALT of acute chemical hepatic injury mice serum, AST, ALT activity, rising liver SOD is active, and reduces liver MDA content.
The above, be only preferred embodiment of the present invention, therefore can not limit according to this scope of the invention process, the equivalence done according to the scope of the claims of the present invention and description changes and modifies, and all should still belong in the scope that the present invention contains.
Claims (9)
1. a control hepatic fibrosis medicines, is characterized in that: comprise the anistree alcohol of main effective ingredient Flos Caryophylli, its application dose is calculated as 5～50mg/70kg body weight every day with the anistree alcohol of Flos Caryophylli.
2. a kind of control hepatic fibrosis medicines as claimed in claim 1, is characterized in that: its application dose is calculated as 5～40mg/70kg body weight every day with the anistree alcohol of Flos Caryophylli.
3. a kind of control hepatic fibrosis medicines as claimed in claim 1, is characterized in that: also comprise one or more in filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, solvent, surfactant, flavouring agent, antiseptic, lubricant, sweeting agent and pigment.
4. a kind of control hepatic fibrosis medicines as claimed in claim 1, is characterized in that: this control hepatic fibrosis medicines is tablet, capsule, granule or syrup.
5. a preparation method of preventing and treating hepatic fibrosis medicines, is characterized in that: this medicine is tablet, comprises the steps:
(1) accurately take the component of following weight portion:
(2) by the anistree alcohol of above-mentioned Flos Caryophylli, microcrystalline Cellulose, stearic acid, lactose and micropowder silica gel mix homogeneously, granulation;
(3) in above-mentioned granule, add above-mentioned magnesium stearate, mix rear tabletting, obtain described control hepatic fibrosis medicines.
6. a kind of preparation method of preventing and treating hepatic fibrosis medicines as claimed in claim 1, is characterized in that:
Described step (1) is: the component that accurately takes following weight portion:
7. the anistree alcohol of Flos Caryophylli is prevented and treated the application in hepatic fibrosis medicines in preparation.
8. application as claimed in claim 7, is characterized in that: the application dose of the anistree alcohol of Flos Caryophylli is 5～50mg/70kg body weight every day.
9. application as claimed in claim 8, is characterized in that: the application dose of the anistree alcohol of Flos Caryophylli is 5～40mg/70kg body weight every day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410322989.8A CN104095832B (en) | 2014-07-08 | 2014-07-08 | A kind of preventing and treating hepatic fibrosis medicines and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410322989.8A CN104095832B (en) | 2014-07-08 | 2014-07-08 | A kind of preventing and treating hepatic fibrosis medicines and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104095832A true CN104095832A (en) | 2014-10-15 |
| CN104095832B CN104095832B (en) | 2016-08-24 |
Family
ID=51664630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410322989.8A Expired - Fee Related CN104095832B (en) | 2014-07-08 | 2014-07-08 | A kind of preventing and treating hepatic fibrosis medicines and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104095832B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050004A (en) * | 2017-04-20 | 2017-08-18 | 郑州大学 | Application of the triphenyl Ne olignan in anti-vancocin resistance enterococcus |
| CN108938638A (en) * | 2018-06-25 | 2018-12-07 | 天津医科大学 | ZINC62678696 inhibits the purposes of hepatic fibrosis medicines in preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083287A (en) * | 2013-01-11 | 2013-05-08 | 华侨大学 | Application of iIllicium macranthum alcohol in preparation of medicine for treating depression |
-
2014
- 2014-07-08 CN CN201410322989.8A patent/CN104095832B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083287A (en) * | 2013-01-11 | 2013-05-08 | 华侨大学 | Application of iIllicium macranthum alcohol in preparation of medicine for treating depression |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050004A (en) * | 2017-04-20 | 2017-08-18 | 郑州大学 | Application of the triphenyl Ne olignan in anti-vancocin resistance enterococcus |
| CN108938638A (en) * | 2018-06-25 | 2018-12-07 | 天津医科大学 | ZINC62678696 inhibits the purposes of hepatic fibrosis medicines in preparation |
| CN108938638B (en) * | 2018-06-25 | 2021-06-08 | 天津医科大学 | Application of ZINC62678696 in preparation of medicine for inhibiting hepatic fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104095832B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435226A (en) | Paederia scandens extract and application thereof | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN104095832A (en) | Liver fibrosis prevention medicine and preparation method thereof | |
| CN102920964B (en) | Traditional Chinese medicine preparation for curing cough | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN1961906A (en) | Diterpene extract of Siegesbeckia, its preparation process and use thereof in phamacy | |
| CN103006781B (en) | Compound Dai medicine extract with liver-protecting effect and preparation method thereof | |
| CN102362916B (en) | Traditional Chinese medicinal compound extract product for protecting liver and preparation method thereof | |
| CN103830374A (en) | Application of three-leaf glycolipid-removal medicine in hyperuricemia | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN104435293B (en) | Application of the Kadsura heteroclita total triterpene ethanol extract in preparation anti-arthritic drugs | |
| CN102406897B (en) | Xingnaojing solid medicinal composition and preparation method thereof | |
| CN105012279B (en) | Composition containing nonyl alcohol and its in application pharmaceutically | |
| CN1299757C (en) | Chinese medicinal composition for treating scapulohumeral periarthritis and preparing method thereof | |
| CN104083393A (en) | Application of dicliptera chinensis polysaccharide in preparation of medicines for treating liver injury caused by antituberculosis drugs | |
| CN101199572B (en) | Medicament of expectorant anti-asthma, preparing method and function thereof | |
| CN104857043A (en) | Radix bupleuri extract and preparation method thereof | |
| CN104739949A (en) | Composition for treating Parkinson disease and preparation method of composition | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN104971100A (en) | Traditional Chinese medicine composition having effects of resisting inflammation and relieving pain, preparation method and application thereof | |
| CN103463453A (en) | Dendrobium stem tablets and extraction and preparation methods thereof | |
| CN100421685C (en) | Chinese material medica preparation in use for treating infection of influenza virus, and preparation method | |
| CN108096229B (en) | Pharmaceutical composition for preventing and treating Alzheimer disease and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 |